Wolfe Research Issues Positive Forecast for Merck & Co., Inc. (NYSE:MRK) Stock Price

Key Points

• Wolfe Research raised Merck’s price target from $155 to $180 and maintained an “outperform” rating, implying approximately 17% upside. The broader analyst consensus is “Moderate Buy,” with an average target of $147.60.
• Merck shares rose 2.1% to $153.85, near their 12-month high of $155.10. The company’s latest quarterly results beat expectations, with revenue of $16.61 billion and EPS of negative $0.13 versus the consensus estimate of negative $0.26.
• Positive Phase 3 results from Merck and Moderna’s personalized cancer-vaccine trial strengthened expectations for expanding Keytruda’s oncology franchise, while institutional investors own 76.07% of the stock; however, insiders sold nearly $30 million in shares during the past quarter.

Merck & Co., Inc. (NYSE:MRK - Get Free Report) had its price objective upped by analysts at Wolfe Research from $155.00 to $180.00 in a report issued on Tuesday,Benzinga reports. The brokerage presently has an "outperform" rating on the stock. Wolfe Research's price target would suggest a potential upside of 17.00% from the company's current price.

A number of other equities research analysts have also issued reports on MRK. BMO Capital Markets raised their price target on Merck & Co., Inc. from $142.00 to $170.00 and gave the stock an "outperform" rating in a research note on Thursday, August 20th. Weiss Ratings downgraded Merck & Co., Inc. from a "hold (c)" rating to a "hold (c-)" rating in a research report on Tuesday, August 11th. Cantor Fitzgerald reiterated a "neutral" rating and set a $120.00 target price on shares of Merck & Co., Inc. in a research report on Monday, July 6th. Wells Fargo & Company boosted their target price on shares of Merck & Co., Inc. from $145.00 to $150.00 and gave the company an "overweight" rating in a research note on Wednesday, July 8th. Finally, Bank of America upped their price target on shares of Merck & Co., Inc. from $130.00 to $141.00 and gave the stock a "buy" rating in a report on Tuesday, June 30th. Fifteen research analysts have rated the stock with a Buy rating and eight have assigned a Hold rating to the company's stock. According to data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and an average target price of $147.60.

Merck & Co., Inc. Trading Up 2.1%

Shares of Merck & Co., Inc. stock traded up $3.19 during trading on Tuesday, hitting $153.85. The stock had a trading volume of 3,201,016 shares, compared to its average volume of 10,838,494. The firm's fifty day simple moving average is $128.81 and its 200-day simple moving average is $121.53. The stock has a market cap of $379.57 billion, a PE ratio of 123.46, a PEG ratio of 6.40 and a beta of 0.19. The company has a debt-to-equity ratio of 1.22, a current ratio of 1.32 and a quick ratio of 1.10. Merck & Co., Inc. has a 12 month low of $77.58 and a 12 month high of $155.10.

Merck & Co., Inc. (NYSE:MRK - Get Free Report) last issued its quarterly earnings results on Tuesday, August 4th. The company reported ($0.13) EPS for the quarter, beating the consensus estimate of ($0.26) by $0.13. The company had revenue of $16.61 billion for the quarter, compared to the consensus estimate of $16.37 billion. Merck & Co., Inc. had a net margin of 4.77% and a return on equity of 16.73%. The firm's revenue was up 5.1% compared to the same quarter last year. During the same period in the prior year, the firm posted $2.13 EPS. Merck & Co., Inc. has set its FY 2026 guidance at 2.660-2.760 EPS. As a group, sell-side analysts expect that Merck & Co., Inc. will post 2.76 EPS for the current fiscal year.

Insider Activity at Merck & Co., Inc.

In other news, EVP David Michael Williams sold 52,847 shares of the business's stock in a transaction dated Wednesday, August 5th. The shares were sold at an average price of $128.77, for a total value of $6,805,108.19. Following the completion of the sale, the executive vice president owned 31,716 shares in the company, valued at approximately $4,084,069.32. The trade was a 62.49% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, EVP David R. Maraldo sold 18,706 shares of the company's stock in a transaction that occurred on Wednesday, August 5th. The stock was sold at an average price of $128.72, for a total transaction of $2,407,836.32. Following the completion of the sale, the executive vice president directly owned 18,212 shares of the company's stock, valued at $2,344,248.64. The trade was a 50.67% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 228,238 shares of company stock worth $29,977,783 over the last quarter. Corporate insiders own 0.17% of the company's stock.

Hedge Funds Weigh In On Merck & Co., Inc.

A number of large investors have recently bought and sold shares of the business. California State Teachers Retirement System boosted its position in Merck & Co., Inc. by 12,537.4% during the 2nd quarter. California State Teachers Retirement System now owns 484,720,247 shares of the company's stock valued at $62,286,552,000 after acquiring an additional 480,884,635 shares in the last quarter. Norges Bank bought a new position in shares of Merck & Co., Inc. in the 4th quarter worth $3,997,933,000. Wellington Management Group LLP lifted its stake in shares of Merck & Co., Inc. by 14.8% during the 4th quarter. Wellington Management Group LLP now owns 86,435,458 shares of the company's stock worth $9,098,196,000 after purchasing an additional 11,156,354 shares during the last quarter. Cardano Risk Management B.V. purchased a new stake in shares of Merck & Co., Inc. during the 4th quarter worth $1,012,530,000. Finally, Jennison Associates LLC purchased a new stake in shares of Merck & Co., Inc. during the 4th quarter worth $585,192,000. Institutional investors own 76.07% of the company's stock.

Key Headlines Impacting Merck & Co., Inc.

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: Argus raised its price target to $170 and upgraded Merck to “Buy,” up from a $145 target. The new target implies roughly 11% upside from the referenced price and reinforces growing Wall Street confidence in Merck’s outlook. Tickerreport.com article
• Positive Sentiment: Positive Phase 3 results from Merck and Moderna’s INTerpath-001 trial showed that the personalized neoantigen therapy intismeran autogene, used with Merck’s Keytruda, cleared a major hurdle in resected melanoma. The results strengthen expectations for a potentially meaningful expansion of Keytruda’s cancer franchise and helped add billions to Merck’s market value. TheStreet article
• Positive Sentiment: The cancer-vaccine data also improved investor confidence in Moderna’s messenger-RNA platform and related personalized cancer treatments, indirectly highlighting the strategic value of Merck’s collaboration and Keytruda combination. Moderna and Merck Cancer Vaccine Success article
• Neutral Sentiment: Market commentary points to a possible rotation away from technology stocks and toward other sectors. That environment may favor relatively defensive large-cap healthcare companies such as Merck, although the broader market shift is not specific to MRK. Jim Cramer market rotation article
• Neutral Sentiment: Merck’s recent move to annual highs reflects a combination of favorable company catalysts and Wall Street price-target increases, but profit-taking across biotechnology shares and mixed market sentiment could contribute to near-term volatility. Stocktwits article

About Merck & Co., Inc.

Merck & Co, Inc is a global biopharmaceutical company engaged in the discovery, development, manufacture and marketing of prescription medicines, vaccines, biologic therapies and animal health products. Its portfolio spans multiple therapeutic areas with a particular emphasis on oncology, vaccines and infectious disease, as well as therapies for metabolic and chronic conditions. Among its well-known products are the cancer immunotherapy Keytruda (pembrolizumab) and the human papillomavirus vaccine Gardasil; the company also markets a range of medicines and vaccines for veterinary use through Merck Animal Health.

Founded in the late 19th century as the U.S.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source